Array Starts First Phase 3 Trial, Shifts to Late-Stage Development

New Drug Approvals

HY-15202

 MEK162

(Synonyms  ARRY-162; ARRY-438162; MEK 162; ARRY 162; ARRY 438162)

MEK162 M.Wt: 441.23
MEK162 Formula: C17H15BrF2N4O3
MEK162 Storage: at -20℃ 2 years
MEK162 CAS No.: 606143-89-9

http://clinicaltrials.gov/ct2/show/NCT00959127

 

Array Starts First Phase 3 Trial, Shifts to Late-Stage Development
Xconomy
Array Biopharma said Tuesday it has received a $5 million milestone payment from Novartis for beginning Phase 3 testing of a drug it hopes can treat ovarian cancer. The milestone is just part of a larger transition for the Boulder, CO-based biopharmaceutical company.

read all at

http://www.xconomy.com/boulder-denver/2013/07/03/array-starts-first-phase-3-trial-shifts-to-late-stage-development/

View original post

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s